Back to Directory

Shane Reynolds

Email

Phone

Institution

FHI 360

Role

Clinical Trials Specialist

Address

FHI 360
359 Blackwell Street
Suite 200
Durham, NC 27701
USA

Request an Update

Affiliated Studies

IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

Locality

US & Non-US

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

11882

Research Area

Treatment

Study Status

Closed to Follow Up

Locality

Non-US

IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

Locality

US & Non-US

P1006: Effects of HAART on Immune Function

DAIDS Number

10036

Research Area

Other

Study Status

Concluded

Locality

United States

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Complications & Comorbidities

Study Status

Enrolling

Locality

United States

Show All